Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Apotex Inc.
WARNING LETTER
•Apotex Inc.•October 26, 2012

Apotex Inc. – FDA Warning Letter, Oct 26, 2012

Record Details

The FDA issued a Warning Letter to Apotex Inc. following inspections from August 13-24, 2012, at their Toronto facility, and October 18-26, 2012, at their Richmond Hill facility, identifying significant violations of CGMP regulations (21 CFR Part 210 and 211). These violations render their drug products adulterated.

At the Toronto facility, violations included: 1. Failure to prevent microbiological contamination of sterile drug products (21 CFR 211.113(b)), specifically inadequate unidirectional airflow studies for aseptic filling lines and failure to establish maximum holding times for media fill vials prior to incubation. 2. Failure to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192), evidenced by releasing partial batches without specific criteria or adequate investigations, and repeat violations of this nature. This also raised concerns about process validation and root cause analysis for issues like tablet defects. 3. Failure to ensure laboratory records included complete data (21 CFR 211.194(a)), such as a microbiologist inaccurately reporting environmental monitoring results.

At the Richmond Hill facility, violations included: 1. Failure to thoroughly investigate batch failures (21 CFR 211.192), specifically not recalling all in-expiry products manufactured on a line that produced a failed sterility test batch

Company
Apotex Inc.
Inspection date
October 26, 2012
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Maan Abduldayem (Consumer safety Officer )
  • Michael D. Smedley
View Company Profile

ID · f5a6262b-3ba8-4a19-8a13-996736fefd13

Violation Codes9
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.113(b)21 CFR 211.19221 CFR 211.194(a)21 U.S.C. 381(a)(3)21 U.S.C. 356C(a)(1)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Apotex Inc.
  • 483 - 2025-04-28April 28, 2025
  • 483 - 2022-09-14September 14, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Apotex Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.